Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Crizotinib hydrochloride (PF-02341066 hydrochloride) 是一种可口服的,具有选择性的 ATP 竞争性双 ALK 和 c-Met 抑制剂。它也是 ROS 原癌基因 1 抑制剂,可抑制肿瘤生长。在细胞的实验中,它抑制 NPM-ALK 的酪氨酸磷酸化和 c-Met 的酪氨酸磷酸化。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 297 | 现货 | ||
10 mg | ¥ 472 | 现货 | ||
50 mg | ¥ 957 | 现货 | ||
100 mg | ¥ 1,390 | 现货 | ||
200 mg | ¥ 1,759 | 现货 | ||
500 mg | ¥ 2,431 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 455 | 现货 |
产品描述 | Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM) |
靶点活性 | ALK:20 nM , c-Met:8 nM |
体外活性 | Crizotinib hydrochloride(PF-2341066)potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC(50) value, 24 nmol/L).?In biochemical and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacologically relevant concentrations across a panel of >120 diverse kinases.?PF-2341066 potently inhibited cell proliferation, which was associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells (IC(50) values, approximately 30 nmol/L) but not ALK-negative lymphoma cells[1]. |
别名 | 克里唑替尼盐酸, PF-02341066 hydrochloride |
分子量 | 486.8 |
分子式 | C21H23Cl3FN5O |
CAS No. | 1415560-69-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.9 mg/mL (10.07 mM)
H2O: 50 mg/mL (102.71 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 2.0542 mL | 10.2712 mL | 20.5423 mL | 51.3558 mL |
5 mM | 0.4108 mL | 2.0542 mL | 4.1085 mL | 10.2712 mL | |
10 mM | 0.2054 mL | 1.0271 mL | 2.0542 mL | 5.1356 mL | |
H2O | 20 mM | 0.1027 mL | 0.5136 mL | 1.0271 mL | 2.5678 mL |
50 mM | 0.0411 mL | 0.2054 mL | 0.4108 mL | 1.0271 mL | |
100 mM | 0.0205 mL | 0.1027 mL | 0.2054 mL | 0.5136 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Crizotinib hydrochloride 1415560-69-8 Angiogenesis Autophagy Immunology/Inflammation Tyrosine Kinase/Adaptors c-Met/HGFR ROS ALK ROS Kinase Crizotinib Hydrochloride 克里唑替尼盐酸 PF02341066 Hydrochloride CD246 PF-02341066 PF 02341066 Hydrochloride ALK tyrosine kinase receptor Anaplastic lymphoma kinase (ALK) PF02341066 PF 02341066 Crizotinib Cluster of differentiation 246 Inhibitor PF-02341066 Hydrochloride inhibit Anaplastic lymphoma kinase PF-02341066 hydrochloride inhibitor